SAN FRANCISCO— Plasma and tumor biomarkers including FGF, C-KIT and VEG-F were found to yield prognostic information which could help guide therapies, according to research findings presented at the 2
SAN FRANCISCO— Plasma and tumor biomarkers including FGF, C-KIT and VEG-F were found to yield prognostic information which could help guide therapies, according to research findings presented at the 2014 ASCO Genitourinary Cancers Conference. Professor Bernard Escudier MD from the Institut Gustave Roussy in Villejuif near Paris discussed results from a biomarker analysis of the multinational phase III randomized GOLD study looking at “third-line” therapy for metastatic renal cell carcinoma with the FGF-directed agent dovitinib compared with sorafenib in patients with metastatic renal cell carcinoma after one prior VEGF pathway–targeted therapy and one prior mTOR inhibitor therapy. High baseline cKIT and low baseline FGF2, HGF, PlGF, sVEGFR1, VEGFA, and VEGFD were associated with better overall survival in patients treated with either sorafenib or dovitinib, and the analysis concluded that baseline plasma biomarkers are prognostic but not predictive in the third-line setting.
CONTACT:
Professor Bernard Escudier MD
Medical Oncologist
Institut Gustave Roussy, France
Unité D’immunology
39 rue Camille-Desmoulins
94805 Villejuif Cedex
France
SOURCE:
Abstract number: 473, ASCO 2014 Genitourinary Cancers Symposium, San Francisco
Author(s):
Bernard J. Escudier, Camillo Porta, Matthew Squires, Cezary Szczylik, Christian K. Kollmannsberger, Bohuslav Melichar, Sun Young Rha, Emilio Esteban, Georg A. Bjarnason, Nicholas J. Vogelzang, Cora N. Sternberg, Michael Shi, Mathab Marker, Robert John Motzer; Institut Gustave Roussy, Villejuif, France; IRCCS San Matteo University Hospital Foundation, Pavia, Italy; Novartis Pharma AG, Basel, Switzerland; Military Institute of Health Services in Warsaw, Warsaw, Poland; BCCA Vancouver Cancer Centre, Vancouver, BC, Canada; Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic; Yonsei University College of Medicine, Seoul, South Korea; Hospital Universitario Central de Asturias, Oviedo, Spain; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Comprehensive Cancer Centers of Nevada, Las Vegas, NV; San Camillo and Forlanini Hospital, Rome, Italy; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Memorial Sloan-Kettering Cancer Center, New York, NY
LINK:
Web link: http://meetinglibrary.asco.org/content/123462-142
Related Episodes
Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls
The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies. I’m Peter Goodwin wi
Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025
Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)
Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy
An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon